ValiRx Plc - VAL201 Clinical Trial Full Data Results
VAL Mon, 30 Nov 2020, 03:30pm GMT
Dr Suzy Dilly, Chief Executive Officer discusses the VAL201 clinical trial results. The full dataset confirms VAL201 is a safe and well-tolerated drug candidate, demonstrating the potential of VAL201 for further development towards a treatment for patients with prostate cancer.
Suzanne Dilly
Chief Executive Officer
Suzanne Dilly, Chief Executive Officer
Mon, 15 Feb 2021, 12:00pm GMT
Dr Suzanne Dilly and Dr Kevin Cox
Tue, 8 Dec 2020, 2:00pm GMT
Suzanne Dilly, Chief Executive Officer
Mon, 30 Nov 2020, 3:30pm GMT
Suzanne Dilly, Chief Executive Officer
Wed, 30 Sep 2020, 9:00am BST
Suzanne Dilly, Chief Executive Officer
Wed, 8 Jul 2020, 3:15pm BST
Dr George Morris, Chief Operating Officer
Wed, 11 Sep 2019, 4:10pm BST
Victoria D'Aquino, Research and Development Officer
Thu, 4 Jul 2019, 9:00am BST
Dr George Morris, Chief Operating Officer
Thu, 20 Jun 2019, 12:20pm BST
Dr George Morris, Chief Operating Officer
Thu, 2 May 2019, 1:16pm BST
Suzanne Dilly, CEO, ValiSeek Limited
Tue, 18 Dec 2018, 12:00pm GMT
Suzanne Dilly, CEO, ValiSeek Limited
Thu, 14 Jun 2018, 11:45am BST
Dr George Morris, Chief Operating Officer
Thu, 19 Apr 2018, 12:15pm BST
Oliver de Giorgio-Miller, Non-Executive Chairman
Tue, 10 Apr 2018, 3:07pm BST
Dr George Morris, Chief Operating Officer
Tue, 6 Feb 2018, 7:00am GMT
Suzanne Dilly, CEO, ValiSeek Limited
Tue, 16 Jan 2018, 7:10am GMT
Dr George Morris, Chief Operating Officer
Thu, 11 Jan 2018, 7:10am GMT
Dr George Morris, Chief Operating Officer
Mon, 18 Dec 2017, 12:30pm GMT
Suzanne Dilly, CEO, ValiSeek Limited
Tue, 12 Dec 2017, 7:30am GMT
